Cortisuzol is a glucocorticoid corticosteroid, discovered by the French company Roussel Uclaf, and claimed to have anti-inflammatory activity in a number of clinical case reports.

Mipimazole was developed as a thyroid inhibitor. However, information about the further development of the drug is not available.

Mazipredone is a glucocorticoid exerting anti-inflammatory, anti-allergic and anti-shock properties.

Quinestradol is an estrogen derivative patented by Francesco Vismara Societa per Azioni and Alberto Ercol for the treatment of senile vulvovaginitis and related conditions. In preclinical trilals, quinestradol shows feminizing action in rats. A clinical trial of Quinestradol appeared to be justified since there was considerable evidence that the preparation was safe and free from side effects.

Nicocortonide is an anti-inflammatory corticosteroid for topical use.

Orestrate was developed as an estrogenic steroid that has never been marketed.

Estrapronicate is a synthetic estrogen exerting anabolic properties.

Seglitide (previously known as L363,586 or MK-678), a cyclic, hexapeptide analog of somatostatin-14, is a somatostatin receptor 2 (SSTR2) agonist. This compound was studied in Alzheimer's disease. Besides, it possessed inhibitory actions on rat growth hormone (GH) release and thus could have a role in the treatment of acromegaly. Intravenous and intranasal administration of seglitide to diabetic subjects was effective in reducing both fasting and postprandial hyperglycemia. Thus, this compound could be useful in the control of unstable diabetes. In addition, preclinical studies have shown that seglitide had potential as a treatment for diabetic retinopathy and macular degeneration. However, the further studied of this compound were discontinued.

Tanaproget (WAY-166989) is a nonsteroidal progesterone receptor agonist. It has been in Phase-II clinical trials as an oral contraceptive. The compound demonstrated a positive preclinical pharmacological profile in the treatment of endometriosis. The level of progesterone receptors in breast tumours can be used to guide the selection of endocrine therapies for breast cancer patients. Radiolabeled analogues of tanaproget have diagnostic potential as PET imaging agents for breast cancer.